contraceptives. 19 Some medications have been reported to have beneficial effects on fibrin clot structure, including aspirin, 5, 20 statins, 12, 21 and antihypertensive agents, 11 by increasing clot permeability and accelerating lysis.
Prothrombotic plasma clot abnormalities are largely driven by changes in plasma concentrations and function of fibrinogen, thrombin, lipoprotein(a), inflammation, as well as post-translational modifications of the fibrinogen molecules, including glycation, homocysteinylation, or carbonylation. 5, 6 Impaired fibrinolysis is associated with elevated plasminogen activator inhibitor-1 (PAI-1), α 2 -antiplasmin, and thrombin activatable fibrinolysis inhibitor. 22 We hypothesized that individuals with LAA thrombi despite no evidence of AF tend to form more compact and lysis-resistant fibrin clots as compared with subjects without LAA thrombi on transesophageal echocardiography (TEE).
In this case-control study, we sought to investigate plasma clot characteristics and their determinants in patients with LAA thrombus as compared with well-matched controls.
Materials and Methods

Patients
In a case-control study, we recruited consecutive patients in sinus rhythm diagnosed with LAA thrombus on TEE after first-ever ischemic stroke, transient ischemic attack (TIA), or migraine associated with patent foramen ovale, who were referred for thrombophilia screening to the Center for Coagulation Disorders in Cracow, Poland, between May 2006 and November 2011. Subjects matched by frequency for age, sex, and diabetes mellitus, who suffered similar clinical manifestations without evidence of LAA thrombus, served as controls. Twenty-four-hour ECG was performed at least twice during the first 3 months from the diagnosis of a cerebrovascular event and the LAA thrombus. All patients in whom LAA thrombi were detected were treated with therapeutic doses of a low molecular weight heparin and then vitamin K antagonists (VKA) for 3 to 6 months. They were eligible if a control echocardiography excluded intracardiac thrombi, and anticoagulation was discontinued 2 to 4 weeks earlier.
A subset of patients (n=13) restarted anticoagulation based on his or her preferences at the physician's discretion. Exclusion criteria were as follows: a documented episode of AF in the past, significant valvular defects, prior myocardial infarction, cardiac surgery, heart failure (New York Heart Association stage III or IV), current anticoagulant therapy, carotid artery stenosis (>30% diameter on ultrasound examination), peripheral artery disease (intermittent claudication or ankle brachial index <0.9), acute infections, or severe comorbidities affecting fibrin properties, for example, malignancy and stage ≥3 chronic kidney disease.
Follow-up started at the time of enrollment and was performed on a 6-month basis (a visit at the center or telephone contact). Ischemic stroke or TIA documented on neuroimaging were recorded during follow-up. Within 7 days since a cerebrovascular episode, transthoracic echocardiography and TEE were performed to exclude or confirm an LAA thrombus. Transthoracic echocardiography was not repeated in asymptomatic patients.
The Jagiellonian University Bioethics Committee approved the study. All subjects signed written informed consent.
Echocardiography
Transthoracic echocardiography and TEE were performed using conventional techniques in accordance with the European Society of Cardiology 23 guidelines in centers where the diagnosis of the LAA thrombus was established and documented in medical records. A thrombus was defined as abnormal echogenic material within the intracavitary space. No contrast agents were used (more information in the online-only Data Supplement).
Laboratory Investigations
Fasting blood was drawn from the antecubital vein using minimal stasis, between 8:00 and 11:00 AM Patients were asked to refrain from cigarette smoking for 2 hours before blood draw. Samples (9:1 of 3.2% trisodium citrate) for coagulation tests were centrifuged (20 minutes, 2500g) within 30 minutes of collection to obtain platelet-poor plasma, immediately frozen, and stored in aliquots at -80°C. Lipid profiles, blood cell counts, glucose, creatinine, D-dimer, and international normalized ratio were assayed by routine laboratory techniques. Fibrinogen was determined using the von Clauss method. High-sensitivity C-reactive protein was measured by latex nephelometry (Siemens, Marburg, Germany). Factor VIII activity was determined by the chromogenic assay (Siemens). von Willebrand factor antigen was measured by latex immunoassay on a STAR coagulation instrument (Diagnostica Stago, Asnieres, France). Tissue-type plasminogen activator, PAI-1, and thrombin activatable fibrinolysis inhibitor antigens were measured by enzyme-linked immunoabsorbent assays (all; American Diagnostica, Stamford, CT). Thrombin-antithrombin complexes (TAT) were measured using an enzyme-linked immunoabsorbent assay (Siemens). Plasma α 2 -antiplasmin and plasminogen were measured by chromogenic assays (STA Stachrom α 2 -antiplasmin and STA Stachrom plasminogen, Diagnostica Stago). Plasma markers of platelet activation, soluble CD40 ligand and P-selectin, were measured using enzyme-linked immunoabsorbent assays (both R&D Systems, Abingdon, UK). The interassay and intra-assay coefficients of variation for the enzyme-linked immunoabsorbent assays were <8%. Technicians blinded to the origin of the samples performed all measurements.
Clot Permeability
Plasma fibrin clot permeability was determined as described. [7] [8] [9] Clot permeability that is proportional to a buffer volume percolating through a clot under a given hydrostatic pressure is the most commonly used measure of clot structure. Briefly, 20 mmol/L calcium chloride and 1 U/mL human thrombin (Sigma) were added to citrated plasma. Tubes containing the clots were connected to a reservoir of a Tris-buffered saline (0.01 mol/L Tris, 0.1 mol/L NaCl, pH 7.5), and its volume flowing through the gels was measured within 60 minutes. A permeation coefficient (K s ), which indicates the average size of pores formed in the fiber network with low values indicating tightly packed fibrin structure, was calculated from the equation: K s =Q×L×η/t×A×Δp, where Q is the flow rate in time t, L is the length of a fibrin gel, η is the viscosity of liquid (in poise), t is percolating time, A is the cross-sectional area (in cm 2 ), and Δp is a differential pressure (in dyne/cm 2 ). The interassay variability was 7.2%.
Clot Lysis
Clot lysis time (CLT) was measured using the turbidity method as described. 8, 16, 17, 22 Briefly, citrated plasma was mixed with 15 mmol/L calcium chloride, 10 000-diluted human tissue factor (Innovin, Siemens) at a final concentration of 0.6 pmol/L, 12 μmol/L phospholipid vesicles, and 60 ng/mL recombinant tissuetype plasminogen activator (Boehringer Ingelheim, Ingelheim, Germany). Measurements were performed at 405 nm at 37°C. CLT was defined as the time from the midpoint of the clear-to-maximum-turbid transition, which represents clot formation, to the midpoint of the maximum-turbid-to-clear transition. The intra-assay variability was 7.8%.
Thrombophilia
Thrombophilia screening, including protein C, protein S, or antithrombin deficiency, factor V Leiden, and prothrombin mutation G20210A, was performed as described. 8, 9 Total plasma homocysteine was measured using the IMX System (Abbott Diagnostics, Wiesbaden, Germany). The diagnosis of antiphospholipid syndrome was established according to Miyakis et al.
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Statistical Analysis
The data are shown as median (interquartile range), mean±standard deviation (SD), or percentage as appropriate. Continuous variables were checked for normal distribution by the Shapiro-Wilk test. The MannWhitney U or Student tests were used as appropriate. The χ 2 test was used to compare the category frequencies. The Pearson or Spearman rank correlation coefficients were calculated to test the association between 2 variables with a normal or non-normal distribution, respectively. The risk of LAA thrombus was estimated as an odds ratio and the corresponding 95% confidence interval using logistic regression, adjusted for age and smoking status. Clinical and echocardiographic variables associated with LAA thrombus were included in the stepwise multiple logistic regression analysis. Two-sided P values of <0.05 were considered statistically significant. Statistical analyses were performed using JMP, Version 9.0.0. SAS Institute Inc, Cary, NC, 1989 to 2007.
The study was powered to have a 90% chance of detecting a 10% difference in CLT using a P value of 0.01, based on previous values. 22 To demonstrate such a difference or greater, ≥32 patients were required in each group. In turn, to demonstrate such a difference or greater in K s using a P value of 0.05, at least 31 patients were required in each group. 25 
Results
A total of 32 patients with documented LAA thrombus were enrolled, and 32 subjects served as controls. There were no intergroup differences in terms of baseline characteristics and cardiovascular risk factors except a higher prevalence of current smokers in the LAA thrombus group (Table 1) . In both groups, the prevalence of deep vein thrombosis and pulmonary embolism was relatively high, with similar proportions of patients with family history of venous thromboembolism (Table 1) . Routine laboratory investigations yielded similar results in both groups (Table I in the online-only Data Supplement). Thrombophilic factors were similarly distributed in both groups (Table 1; Table II in the online-only Data Supplement). Echocardiography showed no differences between groups, with the exception of larger LA volume and diameter observed in the LAA thrombus group (Table III in the online-only Data Supplement).
Thrombotic and Fibrinolysis Markers
As shown in Table 1 
Fibrin Clot Properties
There was a tendency for lower K s in the LAA thrombus group (P=0.07), whereas efficiency of fibrinolysis in this group was impaired as reflected by 20% longer CLT compared with the controls (P=0.0013; 
Predictors of LAA Thrombus
The presence of LAA thrombus was predicted by von Willebrand factor, thrombin activatable fibrinolysis inhibitor antigen, plasminogen, and K s , with the strongest contribution of the latter variable (Table 2) . After adjustment for fibrinogen, occurrence of LAA thrombus was predicted by von Willebrand factor, plasminogen, PAI-1, and K s ( Table 2) .
Follow-Up
A median duration of follow-up was 66 (interquartile range, 49-78.75) months in the LAA thrombus group and 75 (58-84) months in the controls (P=0.022). Three patients were lost to follow-up. Ten (33.3%) patients in the LAA thrombus group (n=30), including 7 (23.3%) with recurrent LAA thrombus, developed stroke or TIA. In this group, 4 (12.9%) subjects had documented paroxysmal AF and stroke or TIA during followup. Six (19.35%) control subjects developed stroke or TIA and 4 (12.9%) patients experienced paroxysmal AF without detection of LAA thrombi during follow-up.
In the LAA thrombus group, aspirin (75 mg/d) was administered in 13 (56.67%) patients, and VKA were continued in 8 (26.67%) patients, including 4 (13.34%) patients on the combination therapy. Similar numbers of treated control subjects were observed, that is, 20 (64.52%), 5 (16.13%), and 0 (P>0.05), respectively. Five patients on aspirin (16.67%), 1 subject on VKA, and 1 on the VKA combined with aspirin developed stroke or TIA and LAA thrombus during followup; the 2 patients on VKA had subtherapeutic international normalized ratio at the time of the event. Corresponding numbers for control subjects were 4, 1, and 0 (P>0.05).
Demographic, clinical, routine laboratory, and echocardiographic variables at baseline did not differ between groups in relation to stroke/TIA or LAA thrombus during follow-up (data not shown). As shown in Table 3 , the patients with recurrent LAA thrombi had higher baseline fibrinogen (P=0.0006), TAT (P=0.0003), soluble CD40 ligand (P=0.019), and lower K s (P=0.001) compared with the remainder, whereas the CLT values were similar with tendency to higher PAI-1 levels (P=0.054). Similar observations were made for 26 patients with LAA thrombi available for analysis during follow-up after exclusion of subjects with patent foramen ovale-associated migraine (Table V and VI in the online-only Data Supplement). The reappearance of LAA thrombi was predicted by low K s (P=0.01), high fibrinogen (P=0.02), and high TAT (P=0.01; Table VII in the online-only Data Supplement). On univariate analysis, high baseline fibrinogen (P=0.01), low K s (P=0.01), high TAT (P=0.02), and low left ventricular ejection fraction (P=0.047) predicted cerebrovascular events observed during follow-up when the LAA thrombus and control groups were combined. On multivariate analysis, FVIII (odds ratio: 0.97 for increase by 1%, 95% confidence interval: 0.948-0.998, β-coefficient: −0.028; P=0.03) and K s (odds ratio: 0.34 for increase by 1 U, 95% confidence interval: 0.172-0.685, β-coefficient: −1.069; P=0.002) were independent negative predictors of cerebrovascular events during follow-up when the 2 groups were combined.
Discussion
To our knowledge, this is the largest case series of patients with a rare abnormality-the presence of LAA thrombus in individuals without history of AF. We observed that patients with LAA thrombi and a recent cerebrovascular event or migraine without documented AF have increased thrombin formation and platelet activation, and they tend to form denser fibrin clots that are resistant to tissue-type plasminogen activator-mediated lysis. Of particular importance is the observation that a high rate of cerebrovascular events in this group during a 5-year follow-up is associated with compact clot structure and elevated thrombin generation after 3 to 6 months' anticoagulation. Our findings indicate that persistent prothrombotic abnormalities might be associated with LAA thrombus as well as its recurrence, although the causality remains to be confirmed.
During follow-up, AF episodes were recorded in 8 patients, 4 in each group (13%). We cannot exclude that a subset of our patients at the time of enrollment had occult AF episodes. This confounding factor is of key importance because altered clot properties have been reported in patients with paroxysmal AF who were in sinus rhythm. 26 It has been demonstrated that a continuous 30-day heart rhythm monitoring after cryptogenic stroke improved the detection of poststroke paroxysmal AF to 14.8% compared with 2.2% observed using standard ECG monitoring. 27 In survivors of TIA or stroke without known AF, this arrhythmia was detected in 4.3% of patients by 72-hour ECG monitoring versus 2.6% during the first 24-hour ECG monitoring. 28 Our diagnostic approach to exclude AF was similar to that recently described in Germany, where in cryptogenic stroke, additional ECG monitoring was recommended by 90.2% of stroke units, but only 13.8% of them performed it routinely. 29 Given the proportions of patients with paroxysmal AF detected during long-term ECG monitoring, a substantial subset of LAA thrombi in our patients could be explained by undetectable paroxysmal AF. In our opinion, it is, however, unlikely that all LAA thrombi result from occult AF
In search for factors that may contribute to LAA thrombus formation, we found that cigarette smoking predisposes to LAA thrombi. It is known that smoking leads to prothrombotic alterations, including endothelial dysfunction, increased platelet adhesiveness and aggregation, impaired fibrinolysis, and more compact fibrin clot networks. 30, 31 This study provides additional evidence for a prothrombotic state in smokers. In contrast to recurrent DVT, 32 elevated D-dimer after anticoagulation withdrawal did not identify patients at risk of the LAA thrombus. Thrombophilic factors did not increase the risk of LAA thrombi in our study, although personal and familial history of venous thromboembolism is common among the patients who experienced this thrombosis, which supports the concept that systemic prothrombotic alterations contribute to thrombosis at unusual sites.
Of note, one third of patients with a history of the LAA thrombus developed stroke or TIA during follow-up. The present study might support the need for long-term anticoagulation in patients with previous LAA thrombus of unknown origin, especially at young age. We observed that denser fibrin clot formation and enhanced thrombin generation can predict both LAA thrombus recurrence and stroke/TIA in the absence of overt cardiac disease, despite a large proportion of patients on aspirin during follow-up. Aspirin and VKA improve fibrin clot properties 5, 6, 33 ; however, they did not abolish the risk of LAA thrombus formation and cerebrovascular events during follow-up.
Our study has several limitations. The size of the study groups was limited because the entity studied is rare. Because patients with LAA thrombi and migraine are at a higher risk of cerebrovascular ischemic events and require anticoagulant therapy, such 6 subjects were enrolled to achieve an adequate study power. However, we cannot exclude different mechanisms predisposing to cerebrovascular events in this small subgroup. Laboratory measurements were done once. Detailed assessment of the LAA morphology was beyond the scope of the current study. The associations reported here do not necessarily mean the cause-effect relationship. A high proportion of patients with previous venous thromboembolism episodes in both groups may affect the data interpretation, and some thrombotic alterations could result from thrombi at sites other than LAA (likely in veins). We did not use thrombosis models to prove causality suggested by the present study. Finally, asymptomatic LAA thrombus recurrence cannot be ruled out.
In conclusion, our observations suggest a significant involvement of prothrombotic abnormalities, including abnormal fibrin properties, in the LAA thrombus formation. Our findings indicate that it is prudent to continue anticoagulation in subjects in whom the LAA thrombus was visualized and if contraindicated or unacceptable by the patient; those subjects should undergo the LAA closure procedure. A prognostic role of the prothrombotic markers in the LAA thrombus remains to be established. 
SUPPLEMENTAL MATERIAL
Supplemental methods
Echocardiography
Left ventricular end-diastolic dimension (LVEDD) and interventricular septum thickness (IVS) were measured in the parasternal long axis view perpendicular to the LV long axis, at or immediately below the level of the mitral valve leaflet tips. The calipers were positioned on the interface between the myocardial wall and cavity and the interface between the wall and the pericardium. Linear measurements were obtained with a two-dimensional (2D) echocardiography or 2D-guided M-mode approach.
Left ventricular mass (LVM) was calculated using the linear method and the following formula: LV mass = 0.8 x 1.04 x [(IVS + LVID + PWT) 3 -LVID 3 ] + 0.6 g. IVS was interventricular septum thickness, LVID was LV internal diameter and PWT was inferolateral wall thickness at end-diastole. All measurements were acquired from the parasternal long-axis view, obtained perpendicular to the LV long axis, and measured at the level of the mitral valve leaflet tips. Left ventricular mass index (LVMI) was obtained by indexing LV mass to body surface area (BSA).
Left ventricular ejection fraction (LVEF) was calculated from end-diastolic (EDV) and end-systolic (ESV) volumes, using the following formula: LVEF = (EDV-ESV)/EDV. The biplane modified Simpson's rule) was used to assess LVEF.
Mitral inflow profile was obtained from Pulsed-wave (PW) Doppler recordings in the apical fourchamber view. The sample volume was place between the mitral leaflet tips during diastole. Spectral mitral velocity recordings were obtained at sweep speed of 50-100 mm/s. E/A ratio was calculated by dividing early (E) to late (A) ventricular filling velocities.
The echocardiographic assessment of mitral insufficiency (MI) included integration of data from TTE/TEE 2D imaging of the valve and ventricle as well as Doppler measures of regurgitation severity. Mild primary mitral regurgitation (MI graded as I or II degree) was recognized while the following qualitative and semi-quantitative parameters were present: small, central regurgitant jet with no/small convergence zone detected by Color Doppler imaging, faint/parabolic Continuous Wave (CW) Doppler signal, vena contracta width less than 3 mm and systolic dominance in pulmonary vein flow.
The anteroposterior diameter of the left atrium (LA) was acquired by TTE at the end of LV systole, in the parasternal long-axis view perpendicular to the aortic root long axis, and measured at the level of the aortic sinuses by using the leading-edge to leading-edge convention.
Left atrial volume (LAV) was measured by TTE 2D approach, based on tracings of the blood-tissue interface on apical four-chamber (A 1 ) and two-chamber (A 2 ) views. LA length (L) was defined as the shortest of the two long axes measured in the apical two-and four-chamber views. LA volume was than computed by using the area-length approximation:
During transesophageal examination (TEE), particular attention was paid to image the main left atrial (LA) cavity and LA appendage (LAA) to assess the presence or absence of spontaneous echo contrast (SEC) and thrombus. Left atrial spontaneous echo contrast was diagnosed by the presence of dynamic smoke-like echoes within the atrial cavity, with a typical swirling motion. Gain settings were adjusted to distinguish SEC from noise artifacts due to excessive gain. The severity of left atrial SEC was graded according to the criteria as follows: 0=absence of echogenicity (SEC), 1(mild)=minimal echogenicity located in the left atrial appendage or sparsely distributed in the main cavity of the left atrium which was detected only transiently during the cardiac cycle and was imperceptible at low gain settings, 2 (mild to moderate)=more dense swirling pattern than grade 1, with similar distribution and detectable without increased gain settings, 3 (moderate)= dense swirling pattern distributed throughout both the LA and the LAA, detectable throughout the cardiac cycle, 4 (severe)=intense echo density and very slow swirling pattern distributed as for 3. Left atrial thrombus was diagnosed by the presence of a clearly defined echo-dense intracavitary mass, distinct from underlying endocardium and not due to the pectinate muscles of the atrial appendage [1] Supplemental tables Deficiency in anticoagulants was defined as protein C activity < 70% of normal, antithrombin activity <75% of normal or free protein S activity <60% of normal. The diagnosis of antiphospholipid syndrome was established based on the modified APS classification criteria by Miyakis et al. [2] . 
